216 related articles for article (PubMed ID: 19118589)
1. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice.
Vlaming ML; Lagas JS; Schinkel AH
Adv Drug Deliv Rev; 2009 Jan; 61(1):14-25. PubMed ID: 19118589
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
3. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.
van Herwaarden AE; Wagenaar E; Merino G; Jonker JW; Rosing H; Beijnen JH; Schinkel AH
Mol Cell Biol; 2007 Feb; 27(4):1247-53. PubMed ID: 17145775
[TBL] [Abstract][Full Text] [Related]
4. Role of ABCG2/BCRP in biology and medicine.
Krishnamurthy P; Schuetz JD
Annu Rev Pharmacol Toxicol; 2006; 46():381-410. PubMed ID: 16402910
[TBL] [Abstract][Full Text] [Related]
5. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin.
Merino G; Jonker JW; Wagenaar E; van Herwaarden AE; Schinkel AH
Mol Pharmacol; 2005 May; 67(5):1758-64. PubMed ID: 15709111
[TBL] [Abstract][Full Text] [Related]
6. ABCG2 -- a transporter for all seasons.
Sarkadi B; Ozvegy-Laczka C; Német K; Váradi A
FEBS Lett; 2004 Jun; 567(1):116-20. PubMed ID: 15165903
[TBL] [Abstract][Full Text] [Related]
7. Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.
Schnepf R; Zolk O
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):287-306. PubMed ID: 23289909
[TBL] [Abstract][Full Text] [Related]
8. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
9. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.
van Herwaarden AE; Schinkel AH
Trends Pharmacol Sci; 2006 Jan; 27(1):10-6. PubMed ID: 16337280
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion.
Merino G; Alvarez AI; Pulido MM; Molina AJ; Schinkel AH; Prieto JG
Drug Metab Dispos; 2006 Apr; 34(4):690-5. PubMed ID: 16434544
[TBL] [Abstract][Full Text] [Related]
11. Human ABC transporter ABCG2 in xenobiotic protection and redox biology.
Wakabayashi K; Tamura A; Saito H; Onishi Y; Ishikawa T
Drug Metab Rev; 2006; 38(3):371-91. PubMed ID: 16877258
[TBL] [Abstract][Full Text] [Related]
12. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy.
Hahnova-Cygalova L; Ceckova M; Staud F
Drug Metab Rev; 2011 Feb; 43(1):53-68. PubMed ID: 20854129
[TBL] [Abstract][Full Text] [Related]
13. Role of ABCG2 in transport of the mammalian lignan enterolactone and its secretion into milk in Abcg2 knockout mice.
Miguel V; Otero JA; García-Villalba R; Tomás-Barberán F; Espín JC; Merino G; Álvarez AI
Drug Metab Dispos; 2014 May; 42(5):943-6. PubMed ID: 24568887
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.
van Herwaarden AE; Wagenaar E; Karnekamp B; Merino G; Jonker JW; Schinkel AH
Carcinogenesis; 2006 Jan; 27(1):123-30. PubMed ID: 16000399
[TBL] [Abstract][Full Text] [Related]
15. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk.
Jonker JW; Merino G; Musters S; van Herwaarden AE; Bolscher E; Wagenaar E; Mesman E; Dale TC; Schinkel AH
Nat Med; 2005 Feb; 11(2):127-9. PubMed ID: 15685169
[TBL] [Abstract][Full Text] [Related]
16. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
17. A model of secreting murine mammary epithelial HC11 cells comprising endogenous Bcrp/Abcg2 expression and function.
Tallkvist J; Yagdiran Y; Danielsson L; Oskarsson A
Cell Biol Toxicol; 2015 Apr; 31(2):111-20. PubMed ID: 25791223
[TBL] [Abstract][Full Text] [Related]
18. Assessment of ABCG2-mediated transport of xenobiotics across the blood-milk barrier of dairy animals using a new MDCKII in vitro model.
Wassermann L; Halwachs S; Baumann D; Schaefer I; Seibel P; Honscha W
Arch Toxicol; 2013 Sep; 87(9):1671-82. PubMed ID: 23652544
[TBL] [Abstract][Full Text] [Related]
19. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
20. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport.
Tamura A; Watanabe M; Saito H; Nakagawa H; Kamachi T; Okura I; Ishikawa T
Mol Pharmacol; 2006 Jul; 70(1):287-96. PubMed ID: 16608919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
